tetano
Editor, Senior Moderator
Blood
. 2020 Jun 3;blood.2020006520.
doi: 10.1182/blood.2020006520. Online ahead of print.
COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection
Hanny Al-Samkari[SUP] 1 [/SUP], Rebecca S Karp Leaf[SUP] 1 [/SUP], Walter H Dzik[SUP] 2 [/SUP], Jonathan Ct Carlson[SUP] 1 [/SUP], Annemarie E Fogerty[SUP] 3 [/SUP], Anem Waheed[SUP] 1 [/SUP], Katayoon Goodarzi[SUP] 1 [/SUP], Pavan Bendapudi[SUP] 4 [/SUP], Larissa Bornikova[SUP] 1 [/SUP], Shruti Gupta[SUP] 5 [/SUP], David Leaf[SUP] 6 [/SUP], David J Kuter[SUP] 7 [/SUP], Rachel P Rosovsky[SUP] 1 [/SUP]
Affiliations
Abstract
Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter, retrospective study described the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically-confirmed VTE rate was 4.8% (95% CI, 2.9-7.3%) and the overall thrombotic complication rate was 9.5% (6.8-12.8%). The overall and major bleeding rates were 4.8% (2.9-7.3%) and 2.3% (1.0-4.2%). In the critically ill, radiographically-confirmed VTE and major bleeding rates were 7.6% (3.9-13.3%) and 5.6% (2.4-10.7%). Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization [D-dimer >2,500 ng/mL, adjusted OR for thrombosis, 6.79 (2.39-19.30), adjusted OR for bleeding, 3.56 (1.01-12.66)], critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450?109/L [adjusted OR, 3.56 (1.27-9.97)], C-reactive protein (CRP) >100 mg/L [adjusted OR, 2.71 (1.26-5.86)], and erythrocyte sedimentation rate >40 mm/h [adjusted OR, 2.64 (1.07-6.51)]. ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than those without. DIC, clinically-relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.
. 2020 Jun 3;blood.2020006520.
doi: 10.1182/blood.2020006520. Online ahead of print.
COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection
Hanny Al-Samkari[SUP] 1 [/SUP], Rebecca S Karp Leaf[SUP] 1 [/SUP], Walter H Dzik[SUP] 2 [/SUP], Jonathan Ct Carlson[SUP] 1 [/SUP], Annemarie E Fogerty[SUP] 3 [/SUP], Anem Waheed[SUP] 1 [/SUP], Katayoon Goodarzi[SUP] 1 [/SUP], Pavan Bendapudi[SUP] 4 [/SUP], Larissa Bornikova[SUP] 1 [/SUP], Shruti Gupta[SUP] 5 [/SUP], David Leaf[SUP] 6 [/SUP], David J Kuter[SUP] 7 [/SUP], Rachel P Rosovsky[SUP] 1 [/SUP]
Affiliations
- PMID: 32492712
- DOI: 10.1182/blood.2020006520
Abstract
Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter, retrospective study described the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically-confirmed VTE rate was 4.8% (95% CI, 2.9-7.3%) and the overall thrombotic complication rate was 9.5% (6.8-12.8%). The overall and major bleeding rates were 4.8% (2.9-7.3%) and 2.3% (1.0-4.2%). In the critically ill, radiographically-confirmed VTE and major bleeding rates were 7.6% (3.9-13.3%) and 5.6% (2.4-10.7%). Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization [D-dimer >2,500 ng/mL, adjusted OR for thrombosis, 6.79 (2.39-19.30), adjusted OR for bleeding, 3.56 (1.01-12.66)], critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450?109/L [adjusted OR, 3.56 (1.27-9.97)], C-reactive protein (CRP) >100 mg/L [adjusted OR, 2.71 (1.26-5.86)], and erythrocyte sedimentation rate >40 mm/h [adjusted OR, 2.64 (1.07-6.51)]. ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than those without. DIC, clinically-relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.